Sodium–glucose cotransporter 2 (SGLT2) inhibitors are recommended agents for the treatment of diabetic kidney disease (DKD). Additionally, SGLT2 inhibitors lower blood glucose, decrease blood pressure, and can be useful for volume management. For these reasons, we hypothesized that initiating SGLT2 inhibitor therapy may be associated with deprescribing of other medications in patients with DKD. We compared medication lists at SGLT2 inhibitor initiation and 6 months post-initiation in 21 patients with DKD who were followed in our interprofessional outpatient nephrology clinic to evaluate deprescribing patterns in diabetes, hypertension, and diuretic medications. Six months of SGLT2 inhibitor therapy in patients with DKD was associated with deprescribing of high-risk diabetes agents, antihypertensives, and loop diuretics with minimal changes in A1C and fewer adverse events.
Medication Optimization for New Initiators of Empagliflozin for Diabetic Kidney Disease
- Views Icon Views
- Share Icon Share
Andrew A. Swanner, Chelsea E. Hawley, Kay Li, Laura K. Triantafylidis, Jiahua Li, Julie M. Paik; Medication Optimization for New Initiators of Empagliflozin for Diabetic Kidney Disease. Clin Diabetes 1 April 2022; 40 (2): 158–167. https://doi.org/10.2337/cd21-0078
Download citation file: